Obstructive hyperthrophic cardiomyopathy
Conditions
Interventions
None listed
Sponsors
Kindai University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Individuals diagnosed with obstructive hypertrophic cardiomyopathy. 2. Individuals who exhibit NYHA functional class II or III symptoms despite receiving standard pharmacological therapies, including beta-blockers, calcium channel blockers, or sodium channel blockers. 3. Individuals with a resting LVEF of 55% or over. 4. Individuals with a resting peak LVOT pressure gradient of 30 mm Hg or over. 5. Individuals who have received a thorough explanation of the study, demonstrated sufficient understanding, and provided written informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1. Individuals who have expressed a desire to decline participation in the study. 2. Individuals who are deemed by the principal investigator to be inappropriate for participation in the study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in index of microvascular resistance (IMR) between pre and post treatment of mavacamten | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in coronary flow reserve 2. Changes in right heart catheterization 3. Relationship between changes in IMR and echocardiographic parameters 4. Relationship between changes in IMR and cardiac magnetic resonance imaging 5. Relationship between changes in IMR and right heart catheterization 6. Relationship between changes in IMR and changes in left ventricular outflow tract gradient | — |
Countries
Japan
Contacts
Public ContactJunna Takuwa
Kindai University, Faculty of Medicine Department of Cardiology
Outcome results
None listed